X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, Seyltx gains access to Algernon’s NP-120 (ifenprodil), an N-methyl-D-aspartate receptor antagonist specifically targeting the NMDA type subunit 2B and a novel first-in-class treatment for idiopathic pulmonary fibrosis and its associated cough.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Seyltx
Deal Size: $2.0 million Upfront Cash: $2.0 million
Deal Type: Acquisition March 27, 2024
Details:
NP-120 (ifenprodil) selectively inhibits N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit. NMDA receptors are ion-channels found within the central and peripheral nervous system, including the area of the brain responsible for coordinating the cough reflex.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
NP-120 (ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. Ifenprodil represents a novel first in class treatment for both IPF and chronic cough.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
NP-120 (ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
NP-120 (ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
The Company will use the proceeds from the offering to fund research and development programs including NP-120 (ifenprodil), and for general and administrative expenses and for working capital purposes.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 23, 2022
Details:
NP-120 (ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signalling. Ifenprodil represents a novel first in class treatment for both IPF and chronic cough.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signalling. Ifenprodil represents a novel first in class treatment for both IPF and chronic cough.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
In the study NP-120 (Ifenprodil), demonstrated 65% of patients had stable or improved forced vital capacity (“FVC”) over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
The net proceeds from the offering of the units will be used to fund research and development programs including NP-120 (Ifenprodil), general and administrative expenses and for working capital purposes.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 04, 2022
Details:
The net proceeds from the offering of the Units will be used to fund research and development programs including NP-120 (ifenprodil), general and administrative expenses and for working capital purposes.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 27, 2022
Details:
Ifenprodil (NP-120), is an N-methyl-D-aspartate receptor antagonist specifically targeting NMDA-type subunit 2B. Ifenprodil prevents glutamate signalling. NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils and certain types of cancer cells.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
The net proceeds from the offering of the units will be used to fund research and development programs including NP-120 (Ifenprodil), general and administrative expenses and for working capital purposes.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering June 15, 2022
Details:
NP-120 (Ifenprodil), is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
NP-120 (ifenprodil) is an N-methyl-D-aspartate receptor antagonist specifically targeting the NMDA-type subunit 2B, Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
Positive trending interim data for NP-120 (Ifenprodil), an N-methyl-D-aspartate (NMDA) receptor antagonist showed a trend in relative reduction in cough count by 40% when compared to each patient’s baseline measurement control.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2022
Details:
The interim analysis examined 24-hour total and waking cough counts measured using an ambulatory cough monitor at baseline and after 4 and 12 weeks of treatment with 20 mg of Ifenprodil, three times daily.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021
Details:
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B) and may represent a potential novel “first-in-class” treatment for chronic cough.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
In pre-IND meeting request application, Company is confirming direction it plans to take in development of Ifenprodil as an adjunct to Topotecan for treatment of chemo refractory small cell lung cancer. Ifenprodil is NMDA receptor antagonist specifically targeting GluN2B.
Lead Product(s): Ifenprodil Tartrate,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: NP-120
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Algernon has signed an exclusive licensing agreement with Dartmouth College to acquire the rights to a method of use patent for Ifenprodil an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Oncology Product Name: NP-120
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Algernon Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 09, 2021
Details:
Administration of 2.5mg/kg Ifenprodil once daily over 10 days reduced PanC-1 tumour xenograft size by almost half with the reduction persisting four days after treatment ceased (p<0.01) while having no apparent impact on animal health.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Oncology Product Name: NP-120
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
One of the biomarkers that was measured was the change in IL-6 levels. In the measurement from baseline to day five, IL-6 was reduced in the 20 mg treatment arm by 267 ng/L, versus 7 ng/L in the standard of care arm by treatment NP-120 (Ifenprodil).
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
Algernon has filed an end of Phase 2 meeting request (EOP2) with the U.S. Food and Drug Administration (“FDA”), based on the completion of the Phase 2b part of its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil).
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021
Details:
The EOP2 meeting will focus on the data from three key endpoints from the Study including all-cause mortality, oxygenation (SpO2) and time in ICU, from the 20mg Ifenprodil treatment arm.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
Algernon Pharmaceuticals has provided an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study. The company reports that the source data audit from all sites and for all patients is now complete.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
Details:
Algernon has decided to review its protocol for its phase 2b/3 study of Ifenprodil for COVID-19, to consider adding lung scarring as an additional endpoint if sufficient data is available from a significant number of patients.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
The Review proposes the repurposing of traditional central nervous system (CNS) drugs that have a high affinity at the sigma-1 receptor, naming Ifenprodil as a potential treatment of SARS-CoV-2-infected patients.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop proprietary injectable and slow release formulations.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
The Company’s multinational Phase 2b/3 human trial for COVID-19 a randomized open label Phase 2b/3 study of the safety and efficacy of NP-120 (Ifenprodil, a GluN2B antagonist) for the treatment of hospitalized patients COVID-19 disease.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
After company's second meeting and review, the external Data and Safety Monitoring Board (“DSMB”) has once again unanimously approved the continuation of the Company’s multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB).
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
External Data and Safety Monitoring Board (DSMB) has unanimously approved the continuation of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The Company’s multinational Phase 2b/3 human trial for COVID-19 is a randomized open label Phase 2b/3 study of the safety and efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
Details:
Algernon Pharmaceuticals has enrolled its first patient in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The countries participating in the study include the U.S., Australia, Romania and the Philippines.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Algernon's multinational Phase 2b/3 human trial for COVID-19 is a randomized open label Phase 2b/3 study of the safety and efficacy of NP-120 (Ifenprodil) for the treatment of hospitalized patients with confirmed COVID-19 disease.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
Algernon has begun screening patients for suitability for enrolment in its Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
The Company is advancing on its multinational Phase 2b/3 human trial for COVID-19 entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: NP-120
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
Algernon has submitted an Investigational New Drug application with the USFDA for its planned multinational Phase 2b/3 study of its re-purposed drug NP-120 as a potential therapeutic treatment for patients with COVID-19. Ifenprodil is an NMDA receptor antagonist.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2020
Details:
Ifenprodil, an NDMA glutamate receptor antagonist exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Upon receiving all ethics approvals, the trial will begin as a Phase IIb study comprising 100 patients.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Phase 2 trial is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
Algernon has received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval for a Phase 2 COVID-19 clinical study of NP-120 (Ifenprodil).
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2020
Details:
The 40-patient, 4-week trial, is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
The study will be an adaptive pilot to pivotal trial design based on WHO guidance documents to assess whether Ifenprodil will improve clinical symptoms and minimize mortality in COVID-19 infection.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
The protocol for a planned physician initiated phase 2 clinical study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea has been finalized.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
Algernon has submitted for ethics approval in Australia for its planned Phase 2 study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
